PubMed Health⌕ Search

Biomedical subjects

J L Pico

Publications and source records attributed to J L Pico.

122 records · Page 7Linked to original sources
PubMed1976

[Angioimmunoblastic adenopathies].

Angio-lymphoblastic lymphadenopathies are a newly described haematological entity, though not rare, characterised by a histological triad (vascular neogenesis, highly polymorphic or predominantly immunoblastic cellular proliferation and the presence of acidophilic protein deposits), a clinical syndrome consisting essentially of voluminous disseminated lymphadenopathy and hepatosplenomegaly and abnormal laboratory findings dominated by a polyclonal dysproteinaemia. This disorder, the first four French cases of which are described here, does not appear to be malignant in its early stages and is sensitive to corticosteroid therapy at that time. Secondary sarcomatous transformation is possible.

Adult↗
PubMed1976

Quantitative variations of three different lectin receptors as a function of establishment and metabolism of normal and leukaemic human cell lines.

Lectin binding on the cell surface was measured by the method of Kornfeld [16] using three tritiated lectins: Robinia pseudo acacia, Concanavalin A and Ricinus. It has been shown that the number of binding sites for Robinia and Con A decreases after the establishment of a leukaemic cell line, whereas the affinity constant increases for Robinia. The relationship between lectin binding and cell growth was carried out on 5 cell lines, 3 of leukaemic and 2 of normal origin. In all cases the maximum number of sites was determined at the time of doubling for the cell population; the affinity constant reciprocally decreases at this moment. For Robinia, a difference was found in both cell growth and the number of sites between an Epstein-Barr virus (EBV) negative leukaemic cell line and the other EBV positive cell lines. Lectins offer a quantitative method for measuring membrane structure variations during and after establishment of cell lines.

Animals↗
PubMed1976

[Value of carcino-embryonic antigen assay in the evaluation and surveillance of breast cancer].

With the method used, the concentrations of carcinoembryonic in antigen serum can be said to be abnormal above 10 ng/ml. The concentrations are normal in benign mastopathies. In 131 cases of breast cancer were studied, they are high in 8 p. cent of T1 and T2 breast cancers, and in 53.9 p. cent of T3 and T4 cancers. They are high in 22 p. cent of cases in the first perceptible phase of their disease, and 92 p. cent relapsed cases. They are also high in 23 p. cent of cases without metastasis, in 32 p. cent of cases with only nodal metastasis, in 82 p. cent of cases with extra-nodal metastasis, and in 94 p. cent of cases with nodal and extra-nodal metastasis. Concentrations of carcinoembryonic in antigen serum which are abnormal before treatment and which do not completely return to normal after treatment, of which rise again, enable one to predict the appearance of a metastasis several months before its clinical manifestation. Determination of the concentrations of carcinoembryonic in antigen serum therefore deserves to become part of the battery of routine for all breast cancers. An initial high concentration is an argument for suggesting systematic chemotherapy. The fluctuations in the concentrations of carcinoembryonic in antigen serum under chemotherapy allow one to assess the efficiency of the treatment.

Breast Neoplasms↗
PubMedDate not supplied

Potential role for low dose limited-field radiation therapy (2 x 2 grays) in advanced low-grade non-Hodgkin's lymphomas.

The purpose of this retrospective study was to evaluate the efficacy of low-dose limited field radiation therapy (LDLRT) in low-grade non-Hodgkin's lymphoma (NHL) patients, in order to outline its possible role. The rationale of the analysis was as follows: (1) there is no clear dose-response relationship for radiation therapy (RT) in localized low-grade non-Hodgkin's lymphomas (LGNHL); (2) long-term disease-free survival can be achieved in advanced LGNHL with low-dose (1.5-2 Gy) fractionated total body irradiation; (3) moreover, some of our previous LGNHL patients stopped their conventional planned RT course for convenience after 5 to 7.5 Gy and remained free from local progression in irradiated volumes for a long period of time. Patient selection criteria were the following: (1) patients with low-grade NHL (LGNHL); (2) patients who received no other form of therapy concomitantly with LDLRT until evaluation of the response; (3) patients who received a planned dose of 4 Gy in two fractions and over 3 days in a limited field. Out of 37 patients, 27 patients were fully evaluable. Twenty-two patients had stage III or IV disease. The median longevity of the disease was 73 months. Twenty-five patients had previously received chemotherapy (18 with anthracyclines). Nineteen patients had received one LDLRT course only. Eight patients responding to the first LDLRT had received at least one subsequent LDLRT course. After the first LDLRT course, an objective response in irradiated sites was observed in 24 of the 27 patients (89 per cent). Ten and 14 patients respectively demonstrated a complete response (CR) (37 per cent) and partial response (PR) (52 per cent). Freedom from progression in irradiated volumes for evaluable patients ranged from 4 to 35 months. Among the eight patients who received at least two LDLRT courses, a total of 20 different areas were irradiated, and 15 areas (75 per cent) showed a CR. Toxicity due to LDLRT was minimal. In conclusion, low-dose limited-field RT resulted in a high proportion of responses in LGNHL. The mechanisms explaining this radioresponsiveness are poorly understood. However, the efficacy of LDLRT could have several clinical applications in the general management of patients with advanced LGNHL.

Adult↗
PubMedDate not supplied

Risk factors for candidemia in patients with acute lymphocytic leukemia.

Between 1983 and 1987 the overall incidence of candidemia at the Institut Gustave Roussy, a tertiary care referral hospital for patients with cancer, increased from 0.1% (7 of 6,801) to 0.32% (24 of 7,515) (P = .009). Because acute lymphocytic leukemia (ALL) was the most common underlying disease in patients with candidemia, risk factors for candidemia were analyzed in this subset of patients. A case-control study comparing the eight ALL patients who had candidemia with 18 ALL control patients revealed that previous bacteremia, prolonged neutropenia, prolonged fever, prolonged administration of antimicrobial agents, treatment with multiple antimicrobial agents, and a relatively high concentration of Candida organisms in stool were significant risk factors for candidemia. In a logistic regression analysis, however, only receipt of vancomycin and/or imipenem was identified as an independent risk factor for candidemia. Further analysis showed that administration of vancomycin promoted proliferation of Candida organisms in the gastrointestinal tract and that this proliferation was associated with an increased risk of candidemia.

Adolescent↗
PubMedDate not supplied

Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: a pilot study.

Vaginal bleeding during aplasia can induce transfusion support, infection and discomfort. Oral and intramuscular hormonotherapy can be toxic and/or difficult to manage (mucositis). This single-center pilot study evaluated the efficacy and safety of leuprorelin (L) in preventing heavy vaginal bleeding in 20 nonmenopausal women with leukemia, lymphoma or myeloma and foreseable therapy-induced thrombocytopenia. Until platelet recovery, patients received subcutaneous injections of L, with concomitant nomegestrol acetate (NA) during the first 35 days to prevent flare-up. Median age was 33 years (18-48). Platelet nadir was < 20 x 10(9)/l in 17 patients; 103 L injections were performed (median per patient: 4 [1-14]). No moderate or severe adverse event was related to hormonal therapy. Seventeen patients did not experience any clinically or therapeutically relevant bleeding. Eleven spottings and 8 metrorrhagias (mean duration: 3 days) occurred in 11 patients, requiring enhanced NA in 3 cases (baseline platelet count was < 20 x 10(9)/l in 1 pt, premature termination of NA [the single platelet transfusion for metrorrhagia] in 1 pt, and endometrial hyperplasia (EH) in the third). In patients without EH, only 5 spottings were observed after the third injection, without neither clinical nor therapeutic impact (63 injections). In conclusion, leuprorelin administration is safe and effective in preventing vaginal bleeding. The sustained-release form and subcutaneous administration offer quality of life advantages.

Adolescent↗
PubMedDate not supplied

[Salvage chemotherapy of non-seminomatous germ cell tumors. Phase II trial of a combination of etoposide, ifosfamide and high-dose cisplatin].

Between october 1985 and january 1988, 32 patients with heavily pretreated refractory or relapsing non seminomatous germ cell tumors were included in a phase II trial using etoposide, ifosfamide and high dose cisplatin (VIhP). Eight of 30 evaluable patients (29 per cent) achieved complete response with VIhP treatment alone or followed by surgical excision of residual lesions. Five patients in complete remission relapsed at 3, 4, 5.5 and 7 months, and 3 patients remained continuously free of disease at 17, 21 and 22 months. Severe myelosuppression with a WBC nadir less than 500/mm3 and a platelet nadir less than 20,000/mm3 was observed in 73 per cent of the patients, and renal toxicity (WHO grade 2 or 3) in 29 per cent. The VIhP regimen for salvage therapy gives the same rate of long term survivors than the regimen with conventional cisplatin dosage (VIP) but is much more toxic and cannot be recommended.

Adolescent↗
PubMedDate not supplied

Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF.

Four out of 23 consecutive patients treated with high-dose Ara-C for lymphomas in our institution developed a strikingly similar syndrome during the perfusion. It was characterized by the onset of fever, diarrhea, shock, pulmonary edema, acute renal failure, metabolic acidosis, weight gain and leukocytosis. Thorough bacteriological screening failed to provide evidence of infection. Sequential biological assays of IL-1, IL-2, TNF and PAF were performed during Ara-C infusion to ten patients, including the four who developed the syndrome. TNF and PAF activity was found in the serum of respectively two and four of the cases, but not in the six controls. As TNF and PAF are thought to be involved in the development of septic shock and adult respiratory distress syndrome, we hypothesize that high-dose Ara-C may be associated with cytokine release.

Acute Kidney Injury↗